Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 189

1.

Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial.

Brown SR, Hall A, Buckley HL, Flanagan L, Gonzalez de Castro D, Farnell K, Moss L, Gregory R, Newbold K, Du Y, Flux G, Wadsley J.

BMC Cancer. 2019 Jun 14;19(1):582. doi: 10.1186/s12885-019-5541-4.

2.

Provider Perspectives on Facilitators and Barriers to Accessible Service Provision for Immigrant Women With Postpartum Depression: A Qualitative Study.

Ganann R, Sword W, Newbold KB, Thabane L, Armour L, Kint B.

Can J Nurs Res. 2019 Sep;51(3):191-201. doi: 10.1177/0844562119852868. Epub 2019 May 28. No abstract available.

PMID:
31137962
3.

Differentiated Thyroid Cancer in Children: A UK Multicentre Review and Review of the Literature.

Lee KA, Sharabiani MTA, Tumino D, Wadsley J, Gill V, Gerrard G, Sindhu R, Gaze MN, Moss L, Newbold K.

Clin Oncol (R Coll Radiol). 2019 Jun;31(6):385-390. doi: 10.1016/j.clon.2019.02.005. Epub 2019 Mar 14.

PMID:
30878210
4.

Journey to Health: (Re) Contextualizing the Health of Canada's Refugee Population.

Newbold KB, McKeary M.

J Refug Stud. 2018 Dec;31(4):687-704. doi: 10.1093/jrs/fey009. Epub 2018 Mar 3.

5.

Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial.

Dehbi HM, Mallick U, Wadsley J, Newbold K, Harmer C, Hackshaw A.

Lancet Diabetes Endocrinol. 2019 Jan;7(1):44-51. doi: 10.1016/S2213-8587(18)30306-1. Epub 2018 Nov 27.

6.

European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium.

Luster M, Aktolun C, Amendoeira I, Barczyński M, Bible KC, Duntas LH, Elisei R, Handkiewicz-Junak D, Hoffmann M, Jarząb B, Leenhardt L, Musholt TJ, Newbold K, Nixon IJ, Smit J, Sobrinho-Simões M, Sosa JA, Tuttle RM, Verburg FA, Wartofsky L, Führer D.

Thyroid. 2019 Jan;29(1):7-26. doi: 10.1089/thy.2017.0129. Epub 2019 Jan 7.

PMID:
30484394
7.

Low prioritization of latent tuberculosis infection-A systemic barrier to tuberculosis control: A qualitative study in Ontario, Canada.

Milinkovic DA, Birch S, Scott F, Newbold KB, Hopkins J, Saffie M, Essue BM.

Int J Health Plann Manage. 2019 Jan;34(1):384-395. doi: 10.1002/hpm.2670. Epub 2018 Nov 7.

PMID:
30402949
8.

Magnetic Resonance-based Response Assessment and Dose Adaptation in Human Papilloma Virus Positive Tumors of the Oropharynx treated with Radiotherapy (MR-ADAPTOR): An R-IDEAL stage 2a-2b/Bayesian phase II trial.

Bahig H, Yuan Y, Mohamed ASR, Brock KK, Ng SP, Wang J, Ding Y, Hutcheson K, McCulloch M, Balter PA, Lai SY, Al-Mamgani A, Sonke JJ, van der Heide UA, Nutting C, Li XA, Robbins J, Awan M, Karam I, Newbold K, Harrington K, Oelfke U, Bhide S, Philippens MEP, Terhaard CHJ, McPartlin AJ, Blanchard P, Garden AS, Rosenthal DI, Gunn GB, Phan J, Cazoulat G, Aristophanous M, McSpadden KK, Garcia JA, van den Berg CAT, Raaijmakers CPJ, Kerkmeijer L, Doornaert P, Blinde S, Frank SJ, Fuller CD.

Clin Transl Radiat Oncol. 2018 Aug 24;13:19-23. doi: 10.1016/j.ctro.2018.08.003. eCollection 2018 Nov.

9.

Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study.

Dillon MT, Grove L, Newbold KL, Shaw H, Brown NF, Mendell J, Chen S, Beckman RA, Jennings A, Ricamara M, Greenberg J, Forster M, Harrington KJ.

Clin Cancer Res. 2019 Jan 15;25(2):487-495. doi: 10.1158/1078-0432.CCR-18-1539. Epub 2018 Oct 16.

PMID:
30327312
10.

Results of a multicentre randomised controlled trial of cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy in patients with parotid cancer (COSTAR; CRUK/08/004).

Nutting CM, Morden JP, Beasley M, Bhide S, Cook A, De Winton E, Emson M, Evans M, Fresco L, Gollins S, Gujral D, Harrington K, Joseph M, Lemon C, Luxon L, van den Blink Q, Mendes R, Miah A, Newbold K, Prestwich R, Robinson M, Sanghera P, Simpson J, Sivaramalingam M, Srihari NN, Sydenham M, Wells E, Witts S, Hall E; COSTAR Investigators.

Eur J Cancer. 2018 Nov;103:249-258. doi: 10.1016/j.ejca.2018.08.006. Epub 2018 Oct 1.

11.

Circulating tumour DNA is a potential biomarker for disease progression and response to targeted therapy in advanced thyroid cancer.

Allin DM, Shaikh R, Carter P, Thway K, Sharabiani MTA, Gonzales-de-Castro D, O'Leary B, Garcia-Murillas I, Bhide S, Hubank M, Harrington K, Kim D, Newbold K.

Eur J Cancer. 2018 Nov;103:165-175. doi: 10.1016/j.ejca.2018.08.013. Epub 2018 Sep 22.

PMID:
30253333
12.

Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer.

Capdevila J, Newbold K, Licitra L, Popovtzer A, Moreso F, Zamorano J, Kreissl M, Aller J, Grande E.

Cancer Treat Rev. 2018 Sep;69:164-176. doi: 10.1016/j.ctrv.2018.06.019. Epub 2018 Jul 2. Review.

PMID:
30032061
13.

Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT).

Wirth LJ, Tahara M, Robinson B, Francis S, Brose MS, Habra MA, Newbold K, Kiyota N, Dutcus CE, Mathias E, Guo M, Sherman SI, Schlumberger M.

Cancer. 2018 Jun 1;124(11):2365-2372. doi: 10.1002/cncr.31344. Epub 2018 Apr 14.

14.

Intensity modulated radiotherapy in locally advanced thyroid cancer: Outcomes of a sequential phase I dose-escalation study.

Rooney KP, Miah AB, Bhide SA, Guerrero-Urbano MT, Sharabiani MT, Newbold KL, Grove L, Harrington KJ, Nutting CM.

Radiother Oncol. 2018 Apr;127(1):43-48. doi: 10.1016/j.radonc.2018.02.002. Epub 2018 Mar 7.

PMID:
29525412
15.

Pregnancy on vandetanib in metastatic medullary thyroid carcinoma associated with multiple endocrine neoplasia type 2B.

Thomas N, Glod J, Derse-Anthony C, Baple EL, Osborne N, Sturley R, Vaidya B, Newbold K, Brooke A.

Clin Endocrinol (Oxf). 2018 May;88(5):754-756. doi: 10.1111/cen.13577. Epub 2018 Mar 8. No abstract available.

16.

Barriers to treatment adherence for individuals with latent tuberculosis infection: A systematic search and narrative synthesis of the literature.

Liu Y, Birch S, Newbold KB, Essue BM.

Int J Health Plann Manage. 2018 Apr;33(2):e416-e433. doi: 10.1002/hpm.2495. Epub 2018 Feb 12. Review.

PMID:
29431235
17.

Incorporating spatial dose metrics in machine learning-based normal tissue complication probability (NTCP) models of severe acute dysphagia resulting from head and neck radiotherapy.

Dean J, Wong K, Gay H, Welsh L, Jones AB, Schick U, Oh JH, Apte A, Newbold K, Bhide S, Harrington K, Deasy J, Nutting C, Gulliford S.

Clin Transl Radiat Oncol. 2018 Jan;8:27-39. doi: 10.1016/j.ctro.2017.11.009. Epub 2017 Nov 21.

18.

Practice patterns for the radical treatment of nasopharyngeal cancer by head and neck oncologists in the United Kingdom.

Petkar I, Bhide S, Newbold K, Harrington K, Nutting C.

Br J Radiol. 2018 May;91(1085):20170590. doi: 10.1259/bjr.20170590. Epub 2018 Feb 13.

19.

MRI-based Assessment of 3D Intrafractional Motion of Head and Neck Cancer for Radiation Therapy.

Gurney-Champion OJ, McQuaid D, Dunlop A, Wong KH, Welsh LC, Riddell AM, Koh DM, Oelfke U, Leach MO, Nutting CM, Bhide SA, Harrington KJ, Panek R, Newbold KL.

Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):306-316. doi: 10.1016/j.ijrobp.2017.10.016. Epub 2017 Oct 16.

20.

Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer.

Tumino D, Frasca F, Newbold K.

Front Endocrinol (Lausanne). 2017 Nov 20;8:312. doi: 10.3389/fendo.2017.00312. eCollection 2017. Review.

21.

Changes in multimodality functional imaging parameters early during chemoradiation predict treatment response in patients with locally advanced head and neck cancer.

Wong KH, Panek R, Dunlop A, Mcquaid D, Riddell A, Welsh LC, Murray I, Koh DM, Leach MO, Bhide SA, Nutting CM, Oyen WJ, Harrington KJ, Newbold KL.

Eur J Nucl Med Mol Imaging. 2018 May;45(5):759-767. doi: 10.1007/s00259-017-3890-2. Epub 2017 Nov 21.

22.

Survey on Paediatric Differentiated Thyroid Cancer Care in Europe.

Dekker BL, Newbold KL, Führer D, Waguespack SG, Handkiewicz-Junak D, Links TP; European Initiative on Collaboration on Paediatric Thyroid Cancer.

Horm Res Paediatr. 2018;89(1):58-62. doi: 10.1159/000484170. Epub 2017 Nov 17.

PMID:
29151082
23.

Predicting response to radical (chemo)radiotherapy with circulating HPV DNA in locally advanced head and neck squamous carcinoma.

Lee JY, Garcia-Murillas I, Cutts RJ, De Castro DG, Grove L, Hurley T, Wang F, Nutting C, Newbold K, Harrington K, Turner N, Bhide S.

Br J Cancer. 2017 Sep 5;117(6):876-883. doi: 10.1038/bjc.2017.258. Epub 2017 Aug 15.

24.

Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial.

Brose MS, Worden FP, Newbold KL, Guo M, Hurria A.

J Clin Oncol. 2017 Aug 10;35(23):2692-2699. doi: 10.1200/JCO.2016.71.6472. Epub 2017 Jun 14.

PMID:
28613956
25.

Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRI.

Panek R, Welsh L, Baker LCJ, Schmidt MA, Wong KH, Riddell AM, Koh DM, Dunlop A, Mcquaid D, d'Arcy JA, Bhide SA, Harrington KJ, Nutting CM, Hopkinson G, Richardson C, Box C, Eccles SA, Leach MO, Robinson SP, Newbold KL.

Clin Cancer Res. 2017 Aug 1;23(15):4233-4241. doi: 10.1158/1078-0432.CCR-16-1209. Epub 2017 Mar 17.

26.

SELIMETRY-a multicentre I-131 dosimetry trial: a clinical perspective.

Wadsley J, Gregory R, Flux G, Newbold K, Du Y, Moss L, Hall A, Flanagan L, Brown SR.

Br J Radiol. 2017 May;90(1073):20160637. doi: 10.1259/bjr.20160637. Epub 2017 Mar 14.

27.

The emerging potential of magnetic resonance imaging in personalizing radiotherapy for head and neck cancer: an oncologist's perspective.

Wong KH, Panek R, Bhide SA, Nutting CM, Harrington KJ, Newbold KL.

Br J Radiol. 2017 Mar;90(1071):20160768. doi: 10.1259/bjr.20160768. Review.

28.

Dysphagia-optimised Intensity-modulated Radiotherapy Techniques in Pharyngeal Cancers: Is Anyone Going to Swallow it?

Petkar I, Bhide S, Newbold K, Harrington K, Nutting C.

Clin Oncol (R Coll Radiol). 2017 Jul;29(7):e110-e118. doi: 10.1016/j.clon.2017.02.002. Epub 2017 Feb 24. Review.

29.

Evaluation of a multi-atlas CT synthesis approach for MRI-only radiotherapy treatment planning.

Guerreiro F, Burgos N, Dunlop A, Wong K, Petkar I, Nutting C, Harrington K, Bhide S, Newbold K, Dearnaley D, deSouza NM, Morgan VA, McClelland J, Nill S, Cardoso MJ, Ourselin S, Oelfke U, Knopf AC.

Phys Med. 2017 Mar;35:7-17. doi: 10.1016/j.ejmp.2017.02.017. Epub 2017 Feb 24.

30.

HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation.

McLaughlin M, Barker HE, Khan AA, Pedersen M, Dillon M, Mansfield DC, Patel R, Kyula JN, Bhide SA, Newbold KL, Nutting CM, Harrington KJ.

BMC Cancer. 2017 Jan 31;17(1):86. doi: 10.1186/s12885-017-3084-0.

31.

Radioiodine for High Risk and Radioiodine Refractory Thyroid Cancer: Current Concepts in Management.

Newbold KL, Flux G, Wadsley J.

Clin Oncol (R Coll Radiol). 2017 May;29(5):307-309. doi: 10.1016/j.clon.2016.12.008. Epub 2017 Jan 27. Review.

PMID:
28139379
32.

Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei.

Dillon MT, Barker HE, Pedersen M, Hafsi H, Bhide SA, Newbold KL, Nutting CM, McLaughlin M, Harrington KJ.

Mol Cancer Ther. 2017 Jan;16(1):25-34. doi: 10.1158/1535-7163.MCT-16-0239. Epub 2016 Nov 9.

33.

Normal Tissue Complication Probability (NTCP) Modelling of Severe Acute Mucositis using a Novel Oral Mucosal Surface Organ at Risk.

Dean JA, Welsh LC, Wong KH, Aleksic A, Dunne E, Islam MR, Patel A, Patel P, Petkar I, Phillips I, Sham J, Schick U, Newbold KL, Bhide SA, Harrington KJ, Nutting CM, Gulliford SL.

Clin Oncol (R Coll Radiol). 2017 Apr;29(4):263-273. doi: 10.1016/j.clon.2016.12.001. Epub 2017 Jan 3.

34.

Blood transfusion during radical chemo-radiotherapy does not reduce tumour hypoxia in squamous cell cancer of the head and neck.

Welsh L, Panek R, Riddell A, Wong K, Leach MO, Tavassoli M, Rahman D, Schmidt M, Hurley T, Grove L, Richards T, Koh DM, Nutting C, Harrington K, Newbold K, Bhide S.

Br J Cancer. 2017 Jan 3;116(1):28-35. doi: 10.1038/bjc.2016.386. Epub 2016 Nov 24.

35.

Time-resolved angiography with stochastic trajectories for dynamic contrast-enhanced MRI in head and neck cancer: Are pharmacokinetic parameters affected?

Panek R, Schmidt MA, Borri M, Koh DM, Riddell A, Welsh L, Dunlop A, Powell C, Bhide SA, Nutting CM, Harrington KJ, Newbold KL, Leach MO.

Med Phys. 2016 Nov;43(11):6024.

PMID:
27806585
36.

Functional Data Analysis Applied to Modeling of Severe Acute Mucositis and Dysphagia Resulting From Head and Neck Radiation Therapy.

Dean JA, Wong KH, Gay H, Welsh LC, Jones AB, Schick U, Oh JH, Apte A, Newbold KL, Bhide SA, Harrington KJ, Deasy JO, Nutting CM, Gulliford SL.

Int J Radiat Oncol Biol Phys. 2016 Nov 15;96(4):820-831. doi: 10.1016/j.ijrobp.2016.08.013. Epub 2016 Aug 22.

37.

DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancer.

Petkar I, Rooney K, Roe JW, Patterson JM, Bernstein D, Tyler JM, Emson MA, Morden JP, Mertens K, Miles E, Beasley M, Roques T, Bhide SA, Newbold KL, Harrington KJ, Hall E, Nutting CM.

BMC Cancer. 2016 Oct 6;16(1):770.

38.

Delayed DNA double-strand break repair following platin-based chemotherapy predicts treatment response in head and neck squamous cell carcinoma.

Bhide SA, Thway K, Lee J, Wong K, Clarke P, Newbold KL, Nutting CM, Harrington KJ.

Br J Cancer. 2016 Sep 27;115(7):825-30. doi: 10.1038/bjc.2016.266. Epub 2016 Sep 1.

39.

Management of Invasive Differentiated Thyroid Cancer.

Nixon IJ, Simo R, Newbold K, Rinaldo A, Suarez C, Kowalski LP, Silver C, Shah JP, Ferlito A.

Thyroid. 2016 Sep;26(9):1156-66. doi: 10.1089/thy.2016.0064. Epub 2016 Aug 23. Review.

40.

CHK1 Inhibition Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy.

Barker HE, Patel R, McLaughlin M, Schick U, Zaidi S, Nutting CM, Newbold KL, Bhide S, Harrington KJ.

Mol Cancer Ther. 2016 Sep;15(9):2042-54. doi: 10.1158/1535-7163.MCT-15-0998. Epub 2016 Jul 15.

41.

The Predictive Value of Early Assessment After 1 Cycle of Induction Chemotherapy with 18F-FDG PET/CT and Diffusion-Weighted MRI for Response to Radical Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma.

Wong KH, Panek R, Welsh L, Mcquaid D, Dunlop A, Riddell A, Murray I, Du Y, Chua S, Koh DM, Bhide S, Nutting C, Oyen WJ, Harrington K, Newbold KL.

J Nucl Med. 2016 Dec;57(12):1843-1850. Epub 2016 Jul 14.

42.

A randomised controlled trial of Caphosol mouthwash in management of radiation-induced mucositis in head and neck cancer.

Wong KH, Kuciejewska A, Sharabiani MTA, Ng-Cheng-Hin B, Hoy S, Hurley T, Rydon J, Grove L, Santos A, Ryugenji M, Bhide SA, Nutting CM, Harrington KJ, Newbold KL.

Radiother Oncol. 2017 Feb;122(2):207-211. doi: 10.1016/j.radonc.2016.06.015. Epub 2016 Jul 5.

43.

Evaluation of radiotherapy techniques for radical treatment of lateralised oropharyngeal cancers : Dosimetry and NTCP.

McQuaid D, Dunlop A, Nill S, Franzese C, Nutting CM, Harrington KJ, Newbold KL, Bhide SA.

Strahlenther Onkol. 2016 Aug;192(8):516-25. doi: 10.1007/s00066-016-0980-1. Epub 2016 Jun 13.

PMID:
27295511
44.

Normal tissue complication probability (NTCP) modelling using spatial dose metrics and machine learning methods for severe acute oral mucositis resulting from head and neck radiotherapy.

Dean JA, Wong KH, Welsh LC, Jones AB, Schick U, Newbold KL, Bhide SA, Harrington KJ, Nutting CM, Gulliford SL.

Radiother Oncol. 2016 Jul;120(1):21-7. doi: 10.1016/j.radonc.2016.05.015. Epub 2016 May 27.

45.

Epstein-Barr virus and carcinomas: rare association of the virus with gastric adenocarcinomas.

Rowlands DC, Ito M, Mangham DC, Reynolds G, Herbst H, Hallissey MT, Fielding JW, Newbold KM, Jones EL, Young LS, Niedobitek G.

Br J Cancer. 2016 Jun 14;114(12):e15. doi: 10.1038/bjc.2016.156. Epub 2016 May 26. No abstract available.

46.

Total Mucosal Irradiation with Intensity-modulated Radiotherapy in Patients with Head and Neck Carcinoma of Unknown Primary: A Pooled Analysis of Two Prospective Studies.

Richards TM, Bhide SA, Miah AB, Del Rosario L, Bodla S, Thway K, Gujral DM, Rooney KP, Schick U, McGovern T, Grove L, Newbold KL, Harrington KJ, Nutting CM.

Clin Oncol (R Coll Radiol). 2016 Sep;28(9):e77-84. doi: 10.1016/j.clon.2016.04.035. Epub 2016 May 11.

48.

Recovery of Salivary Function: Contralateral Parotid-sparing Intensity-modulated Radiotherapy versus Bilateral Superficial Lobe Parotid-sparing Intensity-modulated Radiotherapy.

Miah AB, Gulliford SL, Morden J, Newbold KL, Bhide SA, Zaidi SH, Hall E, Harrington KJ, Nutting CM.

Clin Oncol (R Coll Radiol). 2016 Sep;28(9):e69-76. doi: 10.1016/j.clon.2016.02.009. Epub 2016 Mar 17.

49.

Assessment of fully-automated atlas-based segmentation of novel oral mucosal surface organ-at-risk.

Dean JA, Welsh LC, McQuaid D, Wong KH, Aleksic A, Dunne E, Islam MR, Patel A, Patel P, Petkar I, Phillips I, Sham J, Newbold KL, Bhide SA, Harrington KJ, Gulliford SL, Nutting CM.

Radiother Oncol. 2016 Apr;119(1):166-71. doi: 10.1016/j.radonc.2016.02.022. Epub 2016 Mar 9.

50.

The Management of Medullary Thyroid Carcinoma in the Era of Targeted Therapy.

Ng-Cheng-Hin B, Newbold KL.

Eur Endocrinol. 2016 Mar;12(1):39-43. doi: 10.17925/EE.2016.12.01.39. Epub 2016 Mar 15. Review.

Supplemental Content

Loading ...
Support Center